Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of rimonabant and weight loss on liver fat and adipose tissue metabolism in metabolic syndrome
2006-000819-16Phase 3Active
- Sponsor
- Helsinki University Hospital
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rimonabant in cardiometabolic risk (CMR) (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Change in liver fat content and Change in amount and function of abdominal adipose tissue. Started Feb 2006; status: active.
02
Drugs
rimonabant
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2006-000819-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000819-16.